Antiretroviraux et milieu associatif au Senegal: outils et methodes pour renforcer les capacites des associations et ameliorer le role des communautes dans l'Initiative senegalaise d'acces aux antiretroviraux (ISAAR)

Ce document resulte d'un atelier de sensibilisation sur les ARV et le role potentiel susceptible d'etre joue par les associations dans l'Initiative senegalaise d'acces aux antiretroviraux (ISAARV) tenu a Dakar en mars 2004. Les differents modules de formation utilises durant l'atelier y sont presentes; avec les elements relatifs aux objectifs de la session; la liste du materiel pedagogique utilise; le resume de la methodologie de la session; les informations donnees en reponse aux questions des participants; les posters presentes

Drug Resistance to AIDS; Tuberculosis and Malaria in the African Region

With just 10of the world population; sub-Saharan Africa has the highest burden of HIV/AIDS; tuberculosis and malaria in the world. Both access to and adequate utilization of eff ective treatment with quality-assured medicines are crucial for reducing the disease burden. However; eff orts to improve access to treatment are hampered by the development of HIV; TB and malaria drug resistance. This is a result of genetic mutations and is a major threat to control of HIV/AIDS; TB and malaria. HIV drug resistance can be minimized by good antiretroviral treatment (ART) programmes; removal of barriers to continuous access to ART and reduction of HIVtransmission. Recent surveys conducted at antenatal clinics in several countries in the African Region estimated that HIV resistance to all drug classes is less than 5. A global HIV drug resistance network established in 2001 supports countries in capacity building and guidance on standard procedures for monitoring HIV drug resistance. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are principally a result of inadequate or poorly administered treatment regimens. The new WHO Stop TB Strategy launched in 2006 identifies management of MDR-TB as a core component of TB control. The magnitude of MDR-TB in the African Region is still unknown. In 2007; 27 countries notifi ed MDR-TB cases; and six reported at least one case of XDR-TB. Following widespread resistance to chloroquine and sulphadoxine-pyrimethamine all malaria-endemic countries except two in the Region have changed the treatment policy to artemisinin-based combination therapy (ACT). The main method of monitoring antimalarial drug resistance is through therapeutic efficacy testing. Todate there has been no confi rmed resistance to ACTs in the African Region. Given the emergence and spread of resistance to HIV; TB and malaria drugs; the purpose of this paper is to describe the issues and challenges and propose a way forward with regard to the prevention and control of such resistance

Access to treatment for HIV/AIDS: report of a meeting of international experts; 12-13 June 2001; Washington; DC; USA

This publication is a report of an international experts meeting held in 12-13 June 2003 at Washington (USA); which aims to explore and prioritise operations research questions about access to treatment for HIV/AIDS. Even if the discussions focused on treatment with ARVs; many of the issues raised and the research questions identified also pertain to treatment of opportunistic infections and the provision of palliative and end-of-life care

Prise en charge medicale des patients vivant avec le VIH/sida au Senegal

Ce guide constitue un outil de formation des formateurs au niveau decentralise sur la prise en charge de l'infection par le VIH chez l'enfant et chez l'adulte.Il traite des aspects relatifs a l'organisation du systeme de sante et de soins au Senegal; aux paquets minimum d'activites VIH/sida selon le niveau de la pyramide sanitaire; au depistage de l'infection par le VIH; a la prise en charge medicale de l'enfant et de l'adulte vivant avec le VIH; a la prevention de la transmission mere-enfant du VIH; a la prise en charge des accidents avec exposition au sang; aux procedures standardisees par la prevention des accidents avec exposition au sang; aux soins palliatifs et de fin de vie au cours de l'infection par le VIH